Michael H. Davidson to Antipsychotic Agents
This is a "connection" page, showing publications Michael H. Davidson has written about Antipsychotic Agents.
Connection Strength
4.887
-
The brief negative symptom scale (BNSS): Sensitivity to treatment effects. Schizophr Res. 2018 07; 197:269-273.
Score: 0.577
-
Bl-1020, a new ?-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry. 2012 Sep; 73(9):e1168-74.
Score: 0.399
-
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009 Jun; 166(6):675-82.
Score: 0.316
-
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007 Jul; 93(1-3):117-30.
Score: 0.276
-
Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006 Jul; 189:31-5.
Score: 0.260
-
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005 Oct; 162(10):1888-95.
Score: 0.247
-
Perceived patient threat and neuroleptic dosage. J Nerv Ment Dis. 2003 Feb; 191(2):129-30.
Score: 0.206
-
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry. 2001 May; 62(5):343-6.
Score: 0.182
-
Long-term safety of risperidone. J Clin Psychiatry. 2001; 62 Suppl 21:26-8.
Score: 0.178
-
A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry. 2000 Jun; 15(6):506-14.
Score: 0.171
-
Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial. JAMA Psychiatry. 2019 10 01; 76(10):1009-1017.
Score: 0.163
-
Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial. Schizophr Res. 2019 09; 211:103-104.
Score: 0.161
-
The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. Schizophr Res. 2019 04; 206:325-332.
Score: 0.154
-
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 12 01; 174(12):1195-1202.
Score: 0.140
-
Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry. 1997 Jul 15; 42(2):138-43.
Score: 0.140
-
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017 Mar 01; 174(3):216-229.
Score: 0.134
-
Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am. 1993 Jun; 16(2):313-38.
Score: 0.105
-
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013 Nov; 39(6):1230-41.
Score: 0.105
-
Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry. 1991 Jan; 48(1):73-6.
Score: 0.089
-
Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 1990; 14(6):879-84.
Score: 0.083
-
Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2010 Jan; 71(1):58-65.
Score: 0.082
-
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009 Dec; 115(2-3):97-103.
Score: 0.082
-
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010 May; 36(3):504-9.
Score: 0.076
-
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006 Jul; 85(1-3):254-65.
Score: 0.065
-
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005 May; 162(5):947-53.
Score: 0.060
-
Body mass index and future schizophrenia in Israeli male adolescents. J Clin Psychiatry. 2004 Nov; 65(11):1546-9.
Score: 0.058
-
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry. 2004 Sep; 19(9):898-905.
Score: 0.057
-
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004; 65 Suppl 7:4-18; quiz 19-20.
Score: 0.055
-
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry. 2002; 63 Suppl 9:25-9.
Score: 0.048
-
Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002; 63 Suppl 9:5-11.
Score: 0.048
-
Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Biol Psychiatry. 1996 Oct 15; 40(8):755-60.
Score: 0.033
-
Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res. 2013 Jun; 147(1):132-139.
Score: 0.026
-
A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012 Jun; 73(6):e728-34.
Score: 0.025
-
Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991 Nov; 148(11):1474-86.
Score: 0.024
-
Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res. 1991 Sep; 38(3):285-92.
Score: 0.023
-
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry. 2005 Nov; 13(11):991-8.
Score: 0.016
-
Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry. 1998 Aug; 155(8):1080-6.
Score: 0.009
-
Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry. 1997 Jun; 54(6):559-66.
Score: 0.009
-
Effect of concurrent distraction on communication failures in schizophrenic patients. II. Medication status correlations. Schizophr Res. 1991 Sep; 5(2):153-9.
Score: 0.006